This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1bm7

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1bm7.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1bm7.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1bm7| PDB=1bm7 | SCENE= }}
{{STRUCTURE_1bm7| PDB=1bm7 | SCENE= }}
-
'''HUMAN TRANSTHYRETIN (PREALBUMIN) COMPLEX WITH FLUFENAMIC ACID (2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID)'''
+
===HUMAN TRANSTHYRETIN (PREALBUMIN) COMPLEX WITH FLUFENAMIC ACID (2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID)===
-
==Overview==
+
<!--
-
Insoluble protein fibrils resulting from the self-assembly of a conformational intermediate are implicated as the causative agent in several severe human amyloid diseases, including Alzheimer's disease, familial amyloid polyneuropathy, and senile systemic amyloidosis. The latter two diseases are associated with transthyretin (TTR) amyloid fibrils, which appear to form in the acidic partial denaturing environment of the lysosome. Here we demonstrate that flufenamic acid (Flu) inhibits the conformational changes of TTR associated with amyloid fibril formation. The crystal structure of TTR complexed with Flu demonstrates that Flu mediates intersubunit hydrophobic interactions and intersubunit hydrogen bonds that stabilize the normal tetrameric fold of TTR. A small-molecule inhibitor that stabilizes the normal conformation of a protein is desirable as a possible approach to treat amyloid diseases. Molecules such as Flu also provide the means to rigorously test the amyloid hypothesis, i.e., the apparent causative role of amyloid fibrils in amyloid disease.
+
The line below this paragraph, {{ABSTRACT_PUBMED_9789022}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 9789022 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_9789022}}
==About this Structure==
==About this Structure==
Line 26: Line 30:
[[Category: Sacchettini, J C.]]
[[Category: Sacchettini, J C.]]
[[Category: Thyroxine transport]]
[[Category: Thyroxine transport]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 11:41:31 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jun 30 19:22:27 2008''

Revision as of 16:22, 30 June 2008

Image:1bm7.png

Template:STRUCTURE 1bm7

HUMAN TRANSTHYRETIN (PREALBUMIN) COMPLEX WITH FLUFENAMIC ACID (2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID)

Template:ABSTRACT PUBMED 9789022

About this Structure

1BM7 is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Inhibiting transthyretin conformational changes that lead to amyloid fibril formation., Peterson SA, Klabunde T, Lashuel HA, Purkey H, Sacchettini JC, Kelly JW, Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12956-60. PMID:9789022

Page seeded by OCA on Mon Jun 30 19:22:27 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1bm7"
Personal tools